title: Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients.
abstract: Maraviroc is the first and, so far, the only licensed representative of the class of chemokine receptor type 5 (CCR5) inhibitors used for the treatment of human immunodeficiency virus (HIV) infection. Its safety and efficacy were demonstrated in several clinical trials, and its use was approved in 2007 by the responsible authorities. Some specific issues are correlated with maraviroc and its use. It is the only drug in the antiretroviral armamentarium, which does not interact with the viral enzymes but with a human receptor. Hence, it is able to be long-term effective only if the infecting virus uses, exclusively, the CCR5 receptor. Occurrence and detection of the CCR5 tropism are some of the great challenges of maraviroc use in treatment-experienced patients. Although up to 80% of naive patients harbor CCR5-tropic virus, the occurrence of CXCR4 or other tropisms increases with the duration of HIV infection and treatment. Nonetheless, maraviroc is a potent medication for eligible patients and helps to improve the outcome of antiretroviral treatment (ART) of HIV infection.
authors.affiliation: IFI Institute for Interdisciplinary Medicine, Hamburg, Germany.
authors.forename: Thore
authors.initials: T
authors.lastname: Lorenzen
references.citation: J Gen Virol. 2001 Aug;82(Pt 8):1807-1814
references.pmid: 11457985
references.citation: J Infect Dis. 2010 Mar 15;201(6):803-13
references.pmid: 20151839
references.citation: J Infect Dis. 2005 Aug 1;192(3):466-74
references.pmid: 15995960
references.citation: Nat Med. 1996 Nov;2(11):1240-3
references.pmid: 8898752
references.citation: Antimicrob Agents Chemother. 2007 Feb;51(2):707-15
references.pmid: 17116673
references.citation: Mol Pharmacol. 2005 Apr;67(4):1268-82
references.pmid: 15644495
references.citation: AIDS. 2008 Sep 12;22(14):F11-6
references.pmid: 18753930
references.citation: J Acquir Immune Defic Syndr. 2010 Aug;54(4):394-7
references.pmid: 20009949
references.citation: N Engl J Med. 2008 Oct 2;359(14):1429-41
references.pmid: 18832244
references.citation: Eur J Med Res. 2007 Oct 15;12(9):463-72
references.pmid: 17933728
references.citation: Nat Med. 2005 Nov;11(11):1170-2
references.pmid: 16205738
references.citation: J Virol. 2003 May;77(9):5201-8
references.pmid: 12692222
references.citation: Virology. 2005 Jul 20;338(1):182-99
references.pmid: 15935415
references.citation: Antimicrob Agents Chemother. 1986 Dec;30(6):933-7
references.pmid: 2434024
references.citation: J Virol. 2007 Jan;81(2):441-5
references.pmid: 17079285
references.citation: J Virol. 2007 Mar;81(5):2359-71
references.pmid: 17182681
references.citation: J Exp Med. 2005 Oct 17;202(8):1087-98
references.pmid: 16230476
references.citation: HIV Med. 2002 Apr;3(2):135-45
references.pmid: 12010361
references.citation: Virology. 2006 May 25;349(1):41-54
references.pmid: 16494916
references.citation: Curr Opin HIV AIDS. 2009 Mar;4(2):96-103
references.pmid: 19339947
references.citation: Am J Hum Genet. 1998 Jun;62(6):1507-15
references.pmid: 9585595
references.citation: Curr Opin HIV AIDS. 2009 Nov;4(6):481-7
references.pmid: 20048714
references.citation: N Engl J Med. 2008 Oct 2;359(14):1442-55
references.pmid: 18832245
references.citation: J Virol. 2009 Apr;83(8):3798-809
references.pmid: 19193800
references.citation: Eur J Med Res. 2007 Oct 15;12(9):453-62
references.pmid: 17933727
references.citation: Lancet. 2001 Jun 2;357(9270):1758-61
references.pmid: 11403814
references.citation: Proc Natl Acad Sci U S A. 2000 May 9;97(10):5639-44
references.pmid: 10779565
references.citation: J Infect Dis. 2005 Mar 15;191(6):866-72
references.pmid: 15717260
references.citation: Virology. 2008 Apr 10;373(2):387-99
references.pmid: 18190945
references.citation: Genes Immun. 2006 Apr;7(3):264-8
references.pmid: 16541097
references.citation: AIDS Rev. 2008 Jul-Sep;10(3):143-51
references.pmid: 18820716
references.citation: AIDS Rev. 2004 Apr-Jun;6(2):107-16
references.pmid: 15332433
references.citation: Cell. 1996 Aug 9;86(3):367-77
references.pmid: 8756719
references.citation: J Exp Med. 2006 Jan 23;203(1):35-40
references.pmid: 16418398
references.citation: AIDS Res Hum Retroviruses. 2010 Jan;26(1):13-24
references.pmid: 20055594
references.citation: Clin Infect Dis. 2003 Oct 15;37(8):1102-6
references.pmid: 14523775
references.citation: Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):395-400
references.pmid: 11782552